Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity

BACKGROUND: We conducted a retrospective review of the dose, toxicity, and efficacy of second line gemcitabine plus nab-paclitaxel (G + Nab-P) after FOLFIRINOX in patients with metastatic and locally advanced unresectable pancreatic cancer. METHODS: In this retrospective study, we included all patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yue, Hochster, Howard, Stein, Stacey, Lacy, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597390/
https://www.ncbi.nlm.nih.gov/pubmed/26451276
http://dx.doi.org/10.1186/s40164-015-0025-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597390/
https://www.ncbi.nlm.nih.gov/pubmed/26451276
http://dx.doi.org/10.1186/s40164-015-0025-y

Ejemplares similares